Anavex Life Sciences Corp. (AVXL)
Track the next or latest earnings date for Anavex Life Sciences Corp., review consensus estimates, and see cached AI analysis for recent quarterly results.
Recent earnings news
No recent earnings news is available right now.
Latest earnings date
Time not specified
Fiscal quarter: Dec/2025
EPS estimate: -$0.10
Revenue estimate: N/A
Market cap: $363.27M
AI earnings summary
Company expects over 3-year cash runway at current burn rate with current balance exceeding $120 million. Management outlined multiple development milestones including regulatory updates for blarcamesine across Alzheimer's, Parkinson's, and Rett syndrome programs, plus advancing ANAVEX3-71 toward pivotal schizophrenia studies.
Sentiment and reaction
Sentiment score: +60.00%
Post-earnings price reaction: +12.34%
EPS
Estimate: -$0.10
Actual: -$0.11
Surprise: -10.00%
Revenue
Estimate: N/A
Actual: N/A
Surprise: N/A
Financial highlights
• Net loss: $9.8 million ($0.11 per share) vs $11.6 million ($0.14 per share) prior year - 15% improvement • R&D expenses: $7.3 million vs $11.6 million prior year - 37% reduction in spending • G&A expenses: $3.5 million vs $2.7 million prior year - 30% increase • Cash position: $102.6 million at Sept 30, 2025 vs $132.2 million year earlier - 22% decline • Current cash balance: Over $120 million providing 3+ year runway at current burn rate • No revenue reported (clinical-stage biotechnology company)
Recent earnings history
Browse the calendar week| Date | Quarter | Report window | EPS est. | Revenue est. |
|---|---|---|---|---|
| Feb 09, 2026 | Dec/2025 | Time not specified | -$0.10 | N/A |